New Human Cell-based 3D Model Reveals Insights into How Immune Cells Contribute to Alzheimer’s Disease
The model provides insights into the progression of AD and could help to accelerate the testing of new treatments.
Press ReleaseSep | 8 | 2023
Exercise-Induced Hormone Irisin May Reduce Alzheimer’s Disease Plaque and Tangle Pathology in the Brain
Key Takeaways
- Researchers have used a 3D human neural cell culture model to show that the exercise-induced muscle hormone, irisin, reduces the level of amyloid beta associated with Alzheimer’s disease
- Irisin had this effect by triggering brain cells called astrocytes to increase production of the amyloid beta–degrading enzyme neprilysin
- The findings could lead to new therapeutic strategies for the treatment of Alzheimer’s disease
BOSTON – Researchers who previously developed the first 3D human cell culture models of Alzheimer’s disease (AD) that displays two major hallmarks of the condition—the generation of amyloid beta deposits followed by tau tangles—have now used their model to investigate whether the exercise-induced muscle hormone irisin affects amyloid beta pathology.
As reported in the journal Neuron, the Massachusetts General Hospital (MGH)–led team has uncovered promising results suggesting that irisin-based therapies might help combat AD.
Physical exercise has been shown to reduce amyloid beta deposits in various mouse models of AD, but the mechanisms involved have remained a mystery.
Exercise increases circulating levels of the muscle-derived hormone irisin, which regulates glucose and lipid metabolism in fat tissue and increases energy expenditure by accelerating the browning of white fat tissue.
Studies have revealed that irisin is present in human and mouse brains and that its levels are reduced in patients with AD and in mouse models of the condition.
To test whether irisin plays a causal role in the link between exercise and reduced amyloid beta, Se Hoon Choi, PhD, and Eun Hee Kim, PhD, of the Genetics and Aging Research Unit at MGH, along with additional research colleagues applied the hormone to their 3D cell culture model of AD.
“First, we found that irisin treatment led to a remarkable reduction of amyloid beta pathology,” says Choi. “Second, we showed this effect of irisin was attributable to increased neprilysin activity owing to increased levels of neprilysin secreted from cells in the brain called astrocytes.”
Neprilysin is an amyloid beta–degrading enzyme that has been found to be elevated in the brains of mice with AD that were exposed to exercise or other conditions leading to reduced amyloid beta.
The researchers uncovered even more details about the mechanisms behind irisin’s link to reduced amyloid beta levels. For example, they identified integrin αV/β5 as the receptor that irisin binds to on astrocytes to trigger the cells to increase neprilysin levels.
Furthermore, they discovered that irisin’s binding to this receptor causes reduced signaling of pathways involving two key proteins: extracellular signal-regulated kinase (ERK) and signal activator of transcription 3 (STAT3). Reduced ERK-STAT3 signaling was critical for irisin-induced enhancement of neprilysin.
Previous studies have shown that in mice, irisin injected into the blood stream can make its way into the brain, making it potentially useful as a therapeutic.
“Our findings indicate that irisin is a major mediator of exercise-induced increases in neprilysin levels leading to reduced amyloid beta burden, suggesting a new target pathway for therapies aimed at the prevention and treatment of Alzheimer’s disease,” says Rudolph Tanzi, PhD, a senior author of the study and director of the Genetics and Aging Research Unit.
Additional co-authors include Hyeonwoo Kim, Mark P. Jedrychowski, Grisilda Bakiasi, Joseph Park, Jane Kruskop, Younjung Choi, Sang Su Kwak, Luisa Quinti, Doo Yeon Kim, Christiane D. Wrann, and Bruce M. Spiegelman.
This research was supported by Cure Alzheimer’s Fund (R.E.T., S.H.C., and C.D.W.); JPB Foundation (R.E.T. and B.M.S.); NIH R56AG072054 and 1R21AG062904 (S.H.C. and C.D.W.); Coins for Alzheimer’s Research Trust (S.H.C.), and BrightFocus Foundation Fellowship A2020870F (E.K.).
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In July 2022, Mass General was named #8 in the U.S. News & World Report list of "America’s Best Hospitals." MGH is a founding member of the Mass General Brigham healthcare system.